Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Revenue of Viridian Therapeutics, Inc. (VRDN)
Revenue in 2023 (TTM): $314 K
According to Viridian Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $314 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Viridian Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $314 K | $-1,008,000 | $-235,365,000 | $-237,734,000 | $-237,734,000 |
| 2022 | $1.77 M | $1.02 M | $-129,388,000 | $-129,874,000 | $-125,444,000 |
| 2021 | $2.96 M | $2.34 M | $-79,290,000 | $-79,413,000 | $-79,416,000 |
| 2020 | $1.05 M | $-27,254,000 | $-40,346,000 | $-110,715,000 | $-110,984,000 |
| 2019 | $4.46 M | $-28,332,999 | $-41,038,000 | $-41,873,000 | $-42,420,000 |
| 2018 | $8.39 M | $-22,035,000 | $-31,830,000 | $-32,703,000 | $-32,703,000 |
| 2017 | $4 M | $-15,620,000 | $-26,129,000 | $-26,512,000 | $-26,512,000 |
| 2016 | $3.34 M | $789 K | $-9,485,000 | $-12,674,000 | $-12,674,000 |
| 2015 | $2.54 M | $66 K | $-11,003,000 | $-11,328,000 | $-11,328,000 |
| 2014 | $4.32 M | $1.08 M | $-6,823,000 | $-7,890,000 | $-7,890,000 |
| 2013 | $4.32 M | $1.82 M | $-297,898 | $-2,159,669 | $-2,159,669 |
| 2012 | $4.41 M | $1.36 M | $-2,950,423 | $-5,618,340 | $-7,211,285 |